⏰ #ASH22 LATE BREAKING ABSTRACT ANNOUNCEMENT! ⏰
It's a big year for post-transplant cyclophosphamide (PTCy) and @BMTCTN!
The primary analysis of #BMTCTN1703 is here!
https://t.co/8M6yACHe7m
A thread 🧵/
@ASHClinicalNews@ASH_hematology
Excited to promote the first 2022 Cellular Therapy Conference taking place in Salt Lake City, UT on September 9-10. Thanks to @BldCancerDoc, @TaniaJain11, @NitinJainMD for travelling all the way out to SLC! #binaytarafoundation
https://t.co/gx9fQ7xSFQ
Don't forget to check out the #GVHD Module Series. These modules will help increase knowledge and improve competence in the management of cGVHD by reviewing current and ongoing guidance and therapies. Find all 3 recorded modules in the Learning Center: https://t.co/VBxACT5YAj
Register for the virtual Survivorship SIG Business Meeting. The meeting will honor the 2022 Survivorship SIG Lifetime Achievement and Early-Career Award recipients for their dedication to the field. https://t.co/Y0jdZ3nYoZ
FYI…expect some travel delays today due to the SLC Marathon! Hope it doesn’t cause too much hassle for everyone at #tandem22. Map of affected roads seem here- https://t.co/toWX2vKfw1
Welcome to Salt Lake City and #TandemMeetings22! I’m lucky to be able to commute to the meeting from my own home in SLC and attend the entire conference! Reach out if you have questions about where to go or see in our mountain city. Enjoy #tandem22!
According to a study of more than 1,300 people, aged 18-39, who got BMT for leukemia, lymphoma, and other serious illnesses - young adults may need help returning to work after #BMT. Learn more: https://t.co/Bzax8ncffJ
The ASTCT Survivorship SIG is please to present a webinar on Cardiometabolic Health and Function after HCT on Nov 3, 1pm CT. Don't miss this important educational event! #ASTCT@BMTInfoNet
https://t.co/TwbA6vsQIB